RPR (Dx) w/Refl Titer: What Non-Reactive and Reactive Mean on a Syphilis Screen

FAQ about RPR (DX) W/Refl Titer and Confirmatory Non-Reactive Testing

• What does non-reactive mean on RPR (Dx) w/Refl Titer and confirmatory testing?

  Non-reactive means no reagin antibodies were found in your blood, and it is the expected result on this test — both reference laboratories publish "Non-Reactive" as the reference interval. Nothing further reflexes from it: neither the titer nor the confirmatory test is performed. The qualification is timing. Serology can be non-reactive early in an infection, before antibodies are detectable, and Labcorp's instruction on its traditional-algorithm panel is direct: "If recent exposure is suspected, submit a new sample for testing in 2-4 weeks."

• What does reactive mean on this test?

  Reactive means reagin antibodies were detected. It is a signal rather than a diagnosis, because these antibodies also appear in conditions unrelated to syphilis. On the diagnostic version, a reactive result automatically triggers a titer and a treponemal antibody test on the same sample, and the treponemal test is what distinguishes syphilis from the other causes. On the monitoring version it triggers the titer alone.

• What does "w/Refl" mean on my lab report?

  It means "with reflex" — further testing runs automatically if the first result meets a set condition, without anyone needing to order it. Here a reactive RPR reflexes to an RPR titer, and on the diagnostic version to a confirmatory treponemal antibody test as well. Quest notes that the reflexed tests are performed at an additional charge. A non-reactive RPR reflexes to nothing.

• What is the difference between RPR (Dx) and RPR (Monitor)?

  They are ordered for opposite reasons, and they do not run the same tests. The diagnostic version screens for evidence of infection, and a reactive result reflexes to both a titer and a confirmatory treponemal test. The monitoring version follows someone already diagnosed — Labcorp describes test 006072 as one that "can be used to follow treatment response in patients being treated for syphilis infection," and states that it "should not be used to screen for syphilis infection" — and a reactive result there reflexes to the titer only, with no confirmatory step. Which one you had is printed on your report.

• What is an RPR titer, and how do I read it?

  A titer is a dilution. A titer of 1:16 means the sample still reacted after being diluted sixteenfold, so a larger second number means more antibody. Titers are used to follow disease activity and treatment response rather than to diagnose.

• How much does an RPR titer have to change to mean something?

  Fourfold — a change of two dilutions. The CDC states that "a fourfold change in titer, equivalent to a change of two dilutions (e.g., from 1:16 to 1:4 or from 1:8 to 1:32), is considered necessary for demonstrating a clinically significant difference between two nontreponemal test results." A move from 1:8 to 1:4 is one dilution — not enough on its own to show a real change, which is not the same as showing that nothing changed.

• Can I compare my titer to one from a different laboratory?

  Not reliably. The CDC states that titers from RPR, VDRL and other nontreponemal tests "should not be used interchangeably to manage patients because they are different test methods." If you are tracking results over time, compare results from the same laboratory and the same test.

• My RPR is non-reactive but my treponemal test is reactive. What does that mean?

  First, a point about where that pair came from: this panel cannot produce it. A non-reactive RPR stops the cascade, so the treponemal test is not performed. If you are holding both results, the treponemal test was ordered separately, or your laboratory ran the reverse sequence algorithm, which starts with the treponemal test instead. The combination itself has several explanations: an infection treated in the past — treponemal antibodies usually persist after successful treatment, so this is a recognized pattern years later — later-stage infection, a false-positive treponemal result, or an early infection. The CDC recommends resolving it with "an additional treponemal test... using a different type of treponemal test assay." Which explanation applies depends on your history and any recent exposure, so this is one to go through with your clinician rather than read off a page.

• I was treated for syphilis — why is my treponemal test still reactive?

  Because treponemal antibodies usually persist after treatment. They record that your immune system met the bacterium; they do not measure whether an infection is still active. The CDC states that "the majority of patients who have reactive treponemal tests will have reactive tests for the remainder of their lives, regardless of adequate treatment or disease activity." There is an exception, and it is narrower than it first looks. The CDC reports that "approximately 15%-25% of patients treated for primary syphilis can revert to a nonreactive treponemal test (FTA-ABS and MHA-TP) result within 2-3 years after treatment", with no seroreversion seen in anyone treated at a later stage. Those are two older manual methods. This panel's confirmatory step is a chemiluminescence immunoassay, and the CDC states that "no published data are available that examined whether reversion to a nonreactive treponemal test occurs with an enzyme immunoassay (EIA) or a chemiluminescence immunoassays (CIA) after treatment for syphilis." So seroreversion after early treatment is documented for the older assays and simply unstudied for the one used here. Either way, treatment response is judged from the nontreponemal titer, not from the treponemal test.

• My titer went down after treatment but has not disappeared. Is that a problem?

  It is a recognized outcome with a name. The CDC describes patients in whom nontreponemal antibodies "might decrease less than fourfold after treatment... or might decline appropriately but fail to serorevert and persist for a long period." To serorevert is for the titer to disappear completely. A titer that settles at a low level and stays there is called the serofast state, and it is something your clinician interprets alongside the pre-treatment titer and the time since treatment.

• Can this test be wrong?

  It can be negative when an infection is present, in three ways. The first is timing: syphilis has "an incubation period of 10-90 days" before the first sore appears, and antibodies take time to develop after infection, so serology can be non-reactive early on. The second is the limit of the method itself, and published estimates of it disagree: compared with direct microscopy of a sore, RPR sensitivity in primary syphilis "ranged from 48.7% to 76.1%" across the studies the CDC groups together, while "one study reported a sensitivity of 92.7%". Sensitivity of this family of tests declines in longer-standing infection, though the CDC notes that "no studies involving RPR test performance for latent syphilis have been conducted in the United States". The third is the prozone phenomenon, in which a very large amount of antibody prevents the test reaction from forming; the CDC notes this "can be avoided if the serum sample is diluted before testing."

• What causes a false-positive RPR?

  The CDC lists false-positive nontreponemal results as "associated with multiple medical conditions and factors unrelated to syphilis, including other infections (e.g., HIV), autoimmune conditions, vaccinations, injecting drug use, pregnancy, and older age." This is precisely why, on the diagnostic version, a reactive screen reflexes to a treponemal confirmatory test rather than standing on its own.

• What is the confirmatory test on this panel?

  On Quest test 36126 it is a chemiluminescence treponemal antibody immunoassay — a test for antibodies to the syphilis bacterium itself — run together with the titer when the screen is reactive. Older report forms and directory listings sometimes name FTA-ABS as the confirming test on this panel; the current Quest panel uses the immunoassay instead. Other laboratories use their own equivalent, and the sequence is the same either way: screen first, treponemal confirmation second.

• What is the "traditional" algorithm, and is there another one?

  The traditional algorithm begins with a nontreponemal test — one that detects reagin rather than the bacterium, such as RPR — and confirms reactive samples with a treponemal test. The reverse sequence algorithm does the opposite, beginning with a treponemal immunoassay. The CDC treats both as acceptable, with the choice depending on "laboratory resources, including staff, space and costs, test volume, and patient populations served." This panel uses the traditional order.

• What does RPR stand for?

  Rapid plasma reagin. "Reagin" is the group of antibodies the test detects — antibodies produced during infection that react with a lipid antigen rather than with the bacterium itself. That indirectness is the reason a reactive result needs confirming.

• Why is there no normal range or number for this test?

  Because RPR is not measured on a scale. LOINC 20507-0 classifies it as an ordinal result — a category rather than a quantity — and both reference laboratories publish the expected value as the single word Non-Reactive. Your report gives you a word, and that word is compared against the expected word. The number that does exist on this panel is the titer, and it appears only when the screen is reactive.

• Is this test the same as a syphilis test?

  It is the usual first step of one. RPR is the screening component; a full serologic diagnosis needs the treponemal confirmation that reflexes from a reactive result on the diagnostic version — and even a reactive pair supports past or current infection, with your history deciding which. A non-reactive screen ends the process unless there is a clinical reason to repeat it.

• Do I need to fast or prepare for this test?

  No. Quest specifies no patient preparation for test 36126. It is a routine blood draw, and the specimen is serum.

• What sample does this test use?

  Serum, from a standard blood draw. Quest asks for 3 mL of serum with a 1 mL minimum; Labcorp asks for 1 mL with a 0.5 mL minimum. Samples showing hemolysis or lipemia are rejected.

• Should I be tested again if my result was non-reactive?

  That depends on timing and on your own risk, and it is a question for your clinician rather than for a reference page. The technical point worth carrying into that conversation is that serology can be non-reactive early in an infection: syphilis has "an incubation period of 10-90 days" before the first sore develops, and antibodies take time to appear after infection. Labcorp's own instruction on its traditional-algorithm panel is to "submit a new sample for testing in 2-4 weeks" where recent exposure is suspected.